Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
oleh: Kirstine Jacobsen, Jordi Bertran-Alamillo, Miguel Angel Molina, Cristina Teixidó, Niki Karachaliou, Martin Haar Pedersen, Josep Castellví, Mónica Garzón, Carles Codony-Servat, Jordi Codony-Servat, Ana Giménez-Capitán, Ana Drozdowskyj, Santiago Viteri, Martin R. Larsen, Ulrik Lassen, Enriqueta Felip, Trever G. Bivona, Henrik J. Ditzel, Rafael Rosell
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2017-09-01 |
Deskripsi
EGFR-mutant non-small cell lung cancer are often resistant to EGFR tyrosine kinase inhibitor treatment. In this study, the authors show that resistant tumors display high Akt activation and that a combined treatment with AKT inhibitors causes synergistic tumour growth inhibition in vitro and in vivo.